These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
135 related items for PubMed ID: 14616428
1. Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin. Kumana CR, Tong MK, Li CS, Lauder IJ, Lee JS, Kou M, Walley T, Haycox A, Chan TM. Br J Clin Pharmacol; 2003 Dec; 56(6):670-8. PubMed ID: 14616428 [Abstract] [Full Text] [Related]
2. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes. Orme ME, Jurewicz WA, Kumar N, McKechnie TL. Pharmacoeconomics; 2003 Dec; 21(17):1263-76. PubMed ID: 14986738 [Abstract] [Full Text] [Related]
3. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation. Coukell AJ, Plosker GL. Pharmacoeconomics; 1998 Dec; 14(6):691-708. PubMed ID: 10346420 [Abstract] [Full Text] [Related]
4. [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients]. Sperschneider H, Wagner C, Korn A, Christians U. Med Klin (Munich); 1997 Oct 15; 92(10):589-96. PubMed ID: 9446006 [Abstract] [Full Text] [Related]
5. Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses. Lazzaro C, McKechnie T, McKenna M. J Nephrol; 2002 Oct 15; 15(5):580-8. PubMed ID: 12455727 [Abstract] [Full Text] [Related]
6. Survey of cyclosporin-sparing agent use in Australasian transplant centres. Jones TE. Aust N Z J Med; 1996 Dec 15; 26(6):772-6. PubMed ID: 9028506 [Abstract] [Full Text] [Related]
7. Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. Smith CL, Hampton EM, Pederson JA, Pennington LR, Bourne DW. Pharmacotherapy; 1994 Dec 15; 14(4):471-81. PubMed ID: 7937285 [Abstract] [Full Text] [Related]
8. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Keown P, Niese D. Kidney Int; 1998 Sep 15; 54(3):938-44. PubMed ID: 9734620 [Abstract] [Full Text] [Related]
9. Co-administration of diltiazem and cyclosporine for kidney transplant recipients: a four year follow-up study. Ingsathit A, Sumethkul V, Chalermsanyakorn P, Jirasiritham S. J Med Assoc Thai; 2006 Aug 15; 89 Suppl 2():S235-41. PubMed ID: 17044477 [Abstract] [Full Text] [Related]
10. Formulation of diltiazem affects cyclosporin-sparing activity. Jones TE, Morris RG, Mathew TH. Eur J Clin Pharmacol; 1997 Aug 15; 52(1):55-8. PubMed ID: 9143868 [Abstract] [Full Text] [Related]
11. Long-term follow-up of co-administration of diltiazem and cyclosporine in Chinese kidney transplant recipients. Xue W, Ding X, Tian P, Pan X, Yan H, Hou J, Feng X, Xiang H, Tian X. Ren Fail; 2010 Jan 15; 32(3):314-9. PubMed ID: 20370446 [Abstract] [Full Text] [Related]
12. Influence of diltiazem on renal function and rejection in renal allograft recipients receiving triple-drug immunosuppression: a randomized, double-blind, placebo-controlled study. Ladefoged SD, Pedersen E, Hammer M, Rasmussen KC, Hansen FM, Andersen CB. Nephrol Dial Transplant; 1994 Jan 15; 9(5):543-7. PubMed ID: 8090335 [Abstract] [Full Text] [Related]
13. Economic analysis of Neoral in de novo renal transplant patients in Canada. Kingma I, Ludwin D, Dandavino R, Wolff JL, Loertscher R, Beauregard-Zollinger L, Bacquet P, Boucher S, Rivière M. Clin Transplant; 1997 Feb 15; 11(1):42-8. PubMed ID: 9067694 [Abstract] [Full Text] [Related]
14. Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis. Murphy GJ, Waller JR, Sandford RS, Furness PN, Nicholson ML. Br J Surg; 2003 Jun 15; 90(6):680-6. PubMed ID: 12808614 [Abstract] [Full Text] [Related]
15. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Drugs; 2001 Jun 15; 61(13):1957-2016. PubMed ID: 11708766 [Abstract] [Full Text] [Related]
16. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Noble S, Markham A. Drugs; 1995 Nov 15; 50(5):924-41. PubMed ID: 8586033 [Abstract] [Full Text] [Related]
17. The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations. Jones TE. Clin Pharmacokinet; 1997 May 15; 32(5):357-67. PubMed ID: 9160170 [Abstract] [Full Text] [Related]
18. Cost containment: coadministration of diltiazem with cyclosporine after heart transplantation. Valantine H, Keogh A, McIntosh N, Hunt S, Oyer P, Schroeder J. J Heart Lung Transplant; 1992 May 15; 11(1 Pt 1):1-7; discussion 7-8. PubMed ID: 1540597 [Abstract] [Full Text] [Related]
19. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. Irish W, Sherrill B, Brennan DC, Lowell J, Schnitzler M. Transplantation; 2003 Dec 27; 76(12):1686-90. PubMed ID: 14688516 [Abstract] [Full Text] [Related]
20. Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective. Walters SJ, Whitfield M, Akehurst RL, Chilcott JB. Pharmacoeconomics; 2003 Dec 27; 21(2):129-38. PubMed ID: 12515574 [Abstract] [Full Text] [Related] Page: [Next] [New Search]